drugset / Trial / NCT01928030
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
NaSingle-groupOpen-labelSupportive care
Summary
This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHuPH20 | Protein / enzyme biologic | 450 iu | Subcutaneous |
| Subject | rHuPH20 | Protein / enzyme biologic | 900 iu | Subcutaneous |